Background: Myocardial infarction (MI) is an ischemic wound that recruits millions of leukocytes. MI-associated blood leukocytosis correlates inversely with patient survival, yet the signals driving heightened leukocyte production after MI remain incompletely understood.
from ischemic myocardium into the blood may also signal to the bone marrow to drive hematopoietic stem cells (HSC) proliferation remotely. These post-MI stimuli could act on either HSC directly or niche cells that regulate the bone marrow microenvironment. Data obtained from mice with infection or injected systemic stimuli suggest that circulating danger signals may activate hematopoiesis 8, 9 .
The pro-inflammatory cytokine interleukin-1 beta (IL-1β) may provide one such hematopoiesis activation signal. Increased bone marrow progenitor proliferation after injection of the chemical compound alum, which is used as a vaccination adjuvant, was attenuated in IL-1 receptor deficient mice 10 . IL-1β also stimulates myelopoiesis in obesity 11 . IL-1β is first synthesized as its cytosolic precursor pro-IL-1β and then gives rise to its active form via caspase-1, an enzyme in turn regulated by the NLRP3 inflammasome 12, 13 . IL-1β and IL-1α both signal using the receptor IL-1R1 14, 15 . IL-1R2, the other IL-1 receptor, functions as a decoy for IL-1 16, 17 . Further, IL-1β CIRCULATIONAHA/2015/016160/R2 4 instigates inflammation in atherosclerotic plaque 18 and ischemic myocardium 13 . IL-1β rises in patient serum after acute MI 19 , and both preclinical and clinical pilot data suggest anti-IL-1 therapy can provide benefit after MI [20] [21] [22] and in atherosclerosis [23] [24] [25] .
This study shows that after MI, soluble factors that reach the bone marrow via the circulation significantly accelerate hematopoiesis. Parabiosis experiments revealed that IL-1β stimulates systemic leukocyte production by a) directly acting on hematopoietic stem cells and b) modulating the stem cell microenvironment in the bone marrow. Administration of an anti-mouse IL-1β reduced post-MI emergency hematopoiesis and attenuated leukocytosis. In ApoE -/mice with atherosclerosis, anti-IL-1β therapy moderated leukocyte overproduction, supported resolution of infarct inflammation and ameliorated post-MI heart failure.
METHODS
A detailed methods description is provided in the online supplement.
Experimental animals. We used female C57BL/6J (WT, n = 162), B6.129S7-Il1r1tm1Imx/J (IL1R1 -/-, n = 28) and apolipoprotein E-deficient (ApoE -/-; B6.129P2-Apoetm1Unc/J, n = 24) mice aged 8-12 weeks (The Jackson Laboratories, Bar Harbor, ME, USA) for our studies. We also used transgenic mice expressing green fluorescent protein (GFP) under the Nestinpromoter (Nestin-GFP, n = 10) 26, 27 . Nestin-GFP mice were a gift from Dr. Grigori Enikolopov (Cold Spring Harbor Laboratory, NY, USA). Age-matched mice were randomly allocated either to control or treatment groups. The study was approved by the Subcommittee on Animal Research Care at Massachusetts General Hospital (Boston, MA).
CIRCULATIONAHA/2015/016160/R2 5 Myocardial infarction surgery. Myocardial infarction was induced by permanent ligation of the left anterior descending coronary artery as described previously 3 . Ischemia Reperfusion Injury was induced and assessed as described previously 28 . Please also see the online supplement.
Neutralizing IL-1β. The IL-1β neutralizing antibody was a donation from Novartis (Basel, Switzerland). The antibody selectively binds IL-1β, thus blocking the interaction of the cytokine with its receptors. We used a monoclonal, mouse anti-mouse IL-1β IgG2a/k antibody derived from an IgG1/k antibody as described by Geiger et al. 29 . The in vitro potency IC50 is about 25 pM, and its affinity to murine IL-1β is about 300 pM. The t1/2 in mice is 14 days 30 . We initiated treatment 2 h after induction of MI with subcutaneously injecting 10 mg/kg bodyweight of the IL-1β antibody (or a mouse monoclonal IgG2a antibody raised against cyclosporine A as isotype control). We repeated injections once weekly over the study period.
BrdU experiments.
To assess proliferation, we used FITC/APC BrdU (bromodeoxyuridine) flow kits (BD Bioscience). For these BrdU pulse experiments, one mg BrdU was injected intraperitoneally 24h prior to euthanization and subsequent organ harvest. After surface staining, intracellular BrdU staining was performed according to the manufacturer's protocol.
Flow cytometry and cell sorting procedures are described in the online supplement.
Bone marrow reconstitution. We lethally irradiated WT or IL1R1 -/mice with 950 cGy. We then reconstituted mice with 2x10 6 whole bone marrow cells from either WT or IL1R1 -/mice. Two to four months later mice received coronary ligation. Please also see the online supplement.
Administration of recombinant mouse IL-1β. We injected 2.5 µg of recombinant mouse IL-1β (R&D Systems, MN, USA) i.p. daily over two days as described elsewhere 31 and then harvested the bone marrow 48h after the first administration. 
RESULTS

IL-1β released after MI activates bone marrow hematopoiesis
It is unclear how the hematopoietic system, which responds to acute myocardial ischemia with increased proliferation, receives signals to increase leukocyte production. We asked whether HSC activation relies on a circulating factor, released after MI, that reaches the bone marrow via the blood. To test this hypothesis, we joined the circulation of two wild type mice in parabiosis.
After 2 weeks, a period necessary to establish shared circulation, one parabiont underwent coronary ligation while the other did not. Two days later, we assessed HSC proliferation in the bone marrow of the non-infarcted parabiont by BrdU incorporation (Fig. 1a ). Lin -Sca-1 + c-Kit + CD48 -CD150 + HSC proliferation in non-infarcted parabionts increased significantly ( Fig. 1a ), indicating that factor(s) circulating in blood contribute to hematopoietic activation after MI. In humans, IL-1β levels rise in the blood after MI 19 . Accordingly, we found IL-1β mRNA and protein levels increased in the infarcted heart ( Fig. 1b ), in circulation and in the bone marrow ( Fig. 1c .)
These data indicate this cytokine transfers signals from the site of ischemic injury to the hematopoietic system. Injecting recombinant mouse IL-1β (rmIL-1β) into naive mice triggered HSC proliferation similar to that observed after MI ( Fig. 1d ). We next joined wild type and interleukin-1 receptor 1 knockout mice (IL1R1 -/-) in parabiosis. Two days after coronary artery ligation in one parabiont, increased HSC proliferation observed in the non-ischemic wild type parabionts significantly diminished in IL1R1 -/mice ( Fig. 1a ). Taken together, these data indicate that IL-1β crossed from the circulation of the infarcted parabiont to that of the non-infarcted parabiont and instigated increased HSC proliferation in the bone marrow.
IL-1β effector cells
Bone marrow stromal cells form a microenvironment that harbors hematopoietic stem and progenitor cells (HSPC) 7 . These niche cells maintain hematopoiesis by producing factors that signal to HSPC and regulate their dormancy, retention and lineage bias. Therefore, our next CIRCULATIONAHA/2015/016160/R2 8 question addressed how IL-1β stimulates HSC proliferation: does IL-1β affect hematopoietic cells directly or act on niche cells regulating HSC activity? To address this issue, we investigated which bone marrow cells can sense IL-1β. Using qRT-PCR in FACS-isolated bone marrow cells (for gating; please see Fig. 2a ), we found that HSC, Lin -Sca-1 + c-Kit + (LSK), as well as all stromal cells regulating HSPC activity, including mesenchymal stromal cells, endothelial cells and osteoblasts, express the interleukin-1 receptor 1 ( Fig. 2a ), with higher expression in the non-hematopoietic niche cells. We then reconstituted lethally irradiated wild type mice with whole bone marrow from either wild type (recipients' bone marrow HSC and bone marrow stromal cells are IL1R1 +/+ ) or from IL1R1 -/mice (recipients' bone marrow HSC lack IL1R1 while the bone marrow stromal cell are IL1R1 competent). Four months later, mice underwent coronary ligation. Subsequent analysis showed significantly decreased HSC proliferation in mice reconstituted with IL1R1 -/bone marrow (Fig. 2b ). In these mice, in which hematopoietic but not niche cells were unresponsive to IL-1β, BrdU incorporation in HSC was still markedly above chimeras without MI (Fig. 2b) . The data indicate that IL-1β's hematopoietic effect involves direct as well as indirect action on hematopoietic cells. To compare IL-1β effects on HSC with indirect effects on hematopoiesis via niche cells, we transplanted wild type bone marrow into lethally irradiated IL1R1 -/recipients (Suppl. Fig. 1a ). In this scenario, bone marrow hematopoietic cells are responsive to IL-1β while the marrow's stromal cells are not. In a second group, lethally irradiated WT mice received IL1R1 -/bone marrow, resulting in the opposite situation. We then investigated the relevance of these two scenarios for post MI recovery (Suppl. Fig. 1b and c) . Cardiac function by MRI was similar in both groups 21 days after coronary ligation, and blood leukocyte numbers were also comparable (Suppl. Fig. 1d-1f) indicating that IL-1β's direct action on HSPC and indirect action via stromal cells are equally important for the post MI increase in leukocyte production.
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Neutralizing IL-1β reduces post-MI bone marrow HSPC proliferation and leukocytosis
Thus far, these data show IL-1β involvement in triggering post-MI emergency hematopoiesis.
This activated heart-bone marrow axis may represent a therapeutic target for reducing leukocyte overproduction after MI, a process that may lead to heart failure and secondary ischemic events 5 . To test how IL-1β neutralization changes leukocyte production, we chose the clinically relevant murine version of canakinumab. Treatment began two hours after coronary ligation, and we assessed bone marrow HSPC proliferation by measuring BrdU incorporation 48 hours later. HSC and LSK proliferation were markedly lower in treated mice compared to a control IgG treated cohort that also underwent coronary artery ligation (Fig. 3a ). The treatment effects were somewhat lower than the decrease in HSC proliferation observed in IL-1R -/mice, possibly because IL-1R1 -/mice lack both, IL-1α as well as the IL-1β signaling. Nevertheless, antibody treatment significantly reduced frequencies of HSC and LSK in the active S+G 2 Reduced hematopoietic progenitor activity led to fewer circulating neutrophils on day 3 and decreased neutrophil and Ly6C high monocyte levels on day 7 after MI (Suppl. Fig. 2a and Fig.   3d ).
Neutralizing IL-1β reduces extramedullary hematopoiesis
The bone marrow chimera data indicate that IL-1β may act on bone marrow niche cells. Indeed, anti-IL-1β treatment preserved mRNA levels of VCAM-1, angiopoietin-1 and osteopontin after coronary ligation (Fig. 4a ). Cell-specific treatment effects are shown in Suppl. Fig. 3 . These effects likely contributed to the treatment-induced decrease in myeloid cell production, as angiopoietin-1, osteopontin and CXCL12 regulate hematopoietic progenitor quiescence 32, 33 .
VCAM-1 retains HSPC in the hematopoietic niche. When VCAM-1 expression falls after MI, CIRCULATIONAHA/2015/016160/R2 10 HSPC release into circulation and seed the spleen 3 . Indeed, HSPC release from the bone marrow into the blood decreased in mice treated with the anti-IL-1β antibody (Fig. 4b) .
Consequently, spleens of mice treated with anti-IL-1β antibody contained fewer LSK and GMP (granulocyte-macrophage progenitors) than controls (Fig. 4c) .
Neutralizing IL-1β reduces inflammation in myocardial infarcts
Leukocytes mobilize rapidly to the infarct after onset of ischemia, and, due to their fast turnover, the extent of their accumulation depends on their supply from the circulation 5, 34 . We consequently tested whether lowering blood leukocyte numbers in the anti-IL-1β treatment group would reduce leukocyte recruitment to the ischemic heart. Indeed, we detected fewer recruited myeloid cells on day 3 and 7 after coronary ligation by flow cytometry and immunohistochemistry ( Fig. 5 and Suppl. Fig. 2b ). These data corroborate previous reports by the Frangogiannis group 35, 36 .
Therapeutically targeting IL-1β signaling improves infarct healing and reduces post-MI remodeling
We next evaluated the impact of antibody-mediated IL-1β signaling blockade on infarct healing and post-MI heart failure in ApoE -/mice on high-fat diet. We chose to study dyslipidemic mice because they mimic two aspects of clinical myocardial infarction: an atherogenic milieu and chronically activated innate immunity 37 . Even without MI ApoE -/mice have augmented myelopoiesis due to increased progenitor cycling in the bone marrow 38 and the spleen 39 . In a serial imaging trial, delayed enhancement MRI determined comparable infarct size in both cohorts on day 1 after permanent occlusion of the coronary artery (Fig. 6a) . In a separate cohort, anti-IL-1β treatment did not change ischemia reperfusion injury (Suppl. Fig. 4 ). On day 7 after MI, mice underwent FMT/CT imaging to determine infarct protease activity with a molecular imaging agent (pan-cathepsin reporter) 40 . At this time point, this molecular imaging signal reports on the resolution of cardiac inflammation. FMT/CT revealed that anti-IL-1β treatment significantly reduced protease activity in the infarct (Fig. 6b ) which we located using the hybrid CT modality. Mice were then re-imaged by MRI 3 weeks after MI. In comparison to controls, anti-IL-1β treated ApoE -/mice exhibited smaller end-diastolic volumes and a better preservation of the left ventricular ejection fraction (Fig. 6c ). Histological analysis of wound healing biomarkers in a cohort of WT mice sacrificed on day 7 after coronary ligation showed that anti-IL-1β treatment reduced staining for the myofibroblast marker α smooth muscle actin (αSMA) and collagen-1, while the density of sprouting capillaries in the granulation tissue did not change (Fig. 7a ). In accord with the histological data, TGF-β1 and MMP-3 mRNA fell and TIMP-1 and TIMP-2 mRNA increased in the infarct and borderzone of the treatment group 7 days after coronary ligation (Fig. 7b ). In addition, mRNA levels for the pro-inflammatory genes tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6) fell, concordant with the observed reduction of inflammatory myeloid cells at this time point.
Anti-IL-1β treatment reduces adhesion molecule expression and shifts macrophage phenotype
To explore how local mechanisms may contribute to the observed salient effects of anti-IL-1β treatment, we examined the mRNA levels of adhesion molecules in infarct tissue. IL-1β neutralization reduced ICAM-2 and P-selectin expression, while ICAM-1, VCAM-1 and Eselectin expression were unchanged on day 7 after coronary artery ligation (Fig. 8a) , indicating that reduced IL-1β signaling dampens leukocyte recruitment. We also investigated how IL-1β influences the infarct macrophage phenotype. We isolated CD45 high CD11b high F4/80 high macrophages by flow sorting from 4 day old infarcts and measured mRNA levels of several M1/M2 macrophage markers (Fig. 8b) . Anti-IL-1β treatment shifted macrophage polarization away from the inflammatory M1 phenotype, indicating that anti-IL-1β therapy augments resolution of inflammation in acute infarcts. 35, 42 .
Although the bone marrow generates billions of cells every day, leukocyte numbers in the steady state follow circadian rhythms within tightly regulated boundaries. Only a minor fraction of HSC actively cycle, while the niche cells forming the hematopoietic microenvironment use signals such as CXCL12 to keep stem cells quiescent 7 . In response to infection and other stressors, a variety of signals, including interferons and Toll-like receptor ligands, increase leukocyte output to meet the heightened demand for these innate immune cells during host defense against invading pathogens. These danger signals may act directly on hematopoietic CIRCULATIONAHA/2015/016160/R2 13 stem cells that express receptors to sense danger-associated molecular patterns. Alternatively, alarmins may modulate the activity of niche cells, including endothelial cells and mesenchymal stromal cells, among others 7, 43 . In the setting of cardiovascular disease, blood leukocytosis correlates with mortality 5 ; however, the signals that increase leukocyte production are incompletely understood. In mice with atherosclerosis, insufficient cholesterol efflux from cells may induce increased HSPC cycling in the bone marrow 38 and spleen 39 , thereby leading to hyperlipidemia-associated monocytosis 44 , heightening macrophage recruitment into the vessel wall and progressing inflammation in the plaque. In this regard, a high macrophage burden characterizes plaques that have given rise to MI in humans 45 .
During MI, increased sympathetic nervous system activity may trigger an additional burst of hematopoiesis by reducing bone marrow levels of CXCL12 and SCF, important HSC retention factors that induce quiescence 3 . We hypothesized that circulating factors also contribute to activating hematopoiesis, as seen after infection or other systemic injury. We specifically tested IL-1β because previous studies have implicated this cytokine in regulating hematopoiesis after injection of the chemical compound alum 10 and because IL-1β levels increase after myocardial infarction in rats 46 and humans 19 . Our data indicate that post-MI, IL-1β signaling in the bone marrow acts through two mechanisms: IL-1β directly binds IL-1R1 expressed by HSC and indirectly affects leukocyte production through signaling to the niche cell compartment. In this microenvironment, antagonizing IL-1β preserved several HSC retention factors and inhibited the HSC and LSK release after MI, reducing their migration to the spleen and attenuating extramedullary hematopoiesis.
Systemically neutralizing IL-1β lowers blood levels of inflammatory monocytes and neutrophils.
These myeloid cells drive plaque inflammation, and myeloid cell supply in blood likely influences rates of recruitment into the arterial wall and ischemic myocardium. In atherosclerotic plaque, CIRCULATIONAHA/2015/016160/R2 14 lower leukocyte numbers may lead to smaller lesion size and reduced vulnerability 18, [47] [48] [49] . In the MI, reducing blood leukocytosis supports resolution of inflammation and mitigates subsequent left ventricular dilation. The ejection fraction was preserved 3 weeks after coronary ligation, likely also due to altered macrophage polarization that enhanced myocardial tissue repair 50 . Our observations of IL-1β's system-wide action correlate well with previous reports on its local effects in the infarcted heart 35, 36, 42, 46, 51, 52 .
Our results have direct clinical relevance, as these experiments used a species-appropriate antibody to neutralize IL-1β in mice with MI equivalent to the clinically-approved drug for syndromes associated with function gain of the NALP3 inflammasome, which generates active IL-1β. The large-scale trial CANTOS is testing whether the FDA-approved anti-human IL-1β antibody can limit recurrent events in stable post-MI patients who have residual inflammation, despite full standard-of-care treatments, as gauged by a highly sensitive C-reactive protein concentration in blood above median 41 . The data presented here provide novel mechanistic insight on this drug's actions. Additionally, our results suggest patients who might have recurrent acute MI while receiving anti-IL-1β antibody would not be at greater risk for enhanced post-MI heart failure. Indeed, these observations support a trial in acute MI, a proposition tested in the MRC trial 53 with a much shorter acting IL-1 receptor antagonist that inhibits both the alpha and beta isoforms of this multipotent mediator. Quantified macrophage polarization markers in FACS-sorted infarct macrophages 4d after coronary ligation. qRT-PCR values are relative to GAPDH expression with the "MI+Ctrl IgG" group set as 1 (n = 6 per group, mean ± SD, *p<0.05, Mann-Whitney test).
